BACKGROUND AND PURPOSE: Ankylosing spondylitis (AS) is a kind of rheumatic disease, leading to pain, fatigue, stiffness, and functional impairment, which seriously affects the quality of life. Etanercept, a fully human recombinant protein, has been applied for the treatment of AS. However, there has not been a systematic analysis for its efficacy and safety. METHODS: This meta-analysis of fourteen randomized, double-blind, placebo-controlled clinical trials with 1,570 participants was performed to investigate the efficacy and safety of etanercept, by means of calculating the overall relative risk, and to compare the different responses between the Caucasian population and the Chinese population. RESULTS: Generally, there was sufficient evidence to prove that etanercept has its advantages in both disease activity controlling and symptoms relieving, especially for axial joints compared with peripheric joints, without higher incidence of serious adverse events. INTERPRETATION: Our preliminary analysis provided that the Caucasian population has better response to etanercept treatment, with more treatment-emergent adverse events. Further specially designed clinical trials need to be performed to investigate the different responses between axial and peripheric joints, also between different races.
BACKGROUND AND PURPOSE:Ankylosing spondylitis (AS) is a kind of rheumatic disease, leading to pain, fatigue, stiffness, and functional impairment, which seriously affects the quality of life. Etanercept, a fully human recombinant protein, has been applied for the treatment of AS. However, there has not been a systematic analysis for its efficacy and safety. METHODS: This meta-analysis of fourteen randomized, double-blind, placebo-controlled clinical trials with 1,570 participants was performed to investigate the efficacy and safety of etanercept, by means of calculating the overall relative risk, and to compare the different responses between the Caucasian population and the Chinese population. RESULTS: Generally, there was sufficient evidence to prove that etanercept has its advantages in both disease activity controlling and symptoms relieving, especially for axial joints compared with peripheric joints, without higher incidence of serious adverse events. INTERPRETATION: Our preliminary analysis provided that the Caucasian population has better response to etanercept treatment, with more treatment-emergent adverse events. Further specially designed clinical trials need to be performed to investigate the different responses between axial and peripheric joints, also between different races.
Authors: Walter P Maksymowych; A Robin Poole; Lori Hiebert; Alison Webb; Mirela Ionescu; Tatiana Lobanok; Lindsay King; John C Davis Journal: J Rheumatol Date: 2005-10 Impact factor: 4.666
Authors: Jürgen Braun; Robert Landewé; Kay-Geert A Hermann; John Han; Songkai Yan; Paul Williamson; Désirée van der Heijde Journal: Arthritis Rheum Date: 2006-05
Authors: J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius Journal: Ann Rheum Dis Date: 2005-04-20 Impact factor: 19.103
Authors: John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji Journal: Arthritis Rheum Date: 2003-11
Authors: Andreas F Mavrogenis; Panayiotis D Megaloikonomos; Cyril Mauffrey; Marius M Scarlat; Patrick Simon; Kazuhiro Hasegawa; Samo K Fokter; Pierre Kehr Journal: Eur J Orthop Surg Traumatol Date: 2018-02-14
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372
Authors: Petra Baji; Márta Péntek; Sándor Szántó; Pál Géher; László Gulácsi; Orsolya Balogh; Valentin Brodszky Journal: Eur J Health Econ Date: 2014-05-16